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An essential role for mast cells as modulators of
neutrophils influx in collagen-induced arthritis in
the mouse
Tatiana Aparecida Pimentel1,5, Andre´ Luiz Franco Sampaio2,3,5, Fulvio D’Acquisto2, Mauro Perretti2
and Sonia Maria Oliani1,4
Mast cells are involved in immune disorders so that many of the proinflammatory and tissue destructive mediators
produced by these cells have been implicated in the pathogenesis of rheumatoid arthritis. This scenario prompted us to
investigate the correlation between mast cell degranulation and neutrophil influx within the digits and knees joints of
arthritic mice assessing what could be the functional role(s) of joint mast cells in the response to collagen immunization.
DBA/1J mice were submitted to collagen-induced arthritis and disease was assessed on day 21, 32 and 42 post-immunization.
Pharmacological treatment with the glucocorticoid prednisolone, commonly used in the clinic, and nedocromil, a mast
cell stabilizer, was performed from day 21 to 30. Arthritis develop after immunization, gradually increased up to day 42.
Neutrophil infiltration peaked on day 32 and 21, in the digits and knees, respectively, showing an unequal pattern of
recruitment between these tissues. This difference emerged for mast cells: they peaked in the digits on day 21, but
a higher degree of degranulation could be measured in the knee joints. Uneven modulation of arthritis occurred after
treatment of mice with prednisolone or nedocromil. Neutrophils migration to the tissue was reduced after both therapies,
but only prednisolone augmented mast cell migration to the joints. Nedocromil exerted inhibitory properties both on
mast cell proliferation and migration, more effectively on the digit joints. Thus, collagen induced an inflammatory process
characterized by tissue mast cells activation and degranulation, suggesting a potential driving force in propagating
inflammatory circuits yielding recruitment of neutrophils. However, the different degree of affected joint involvement
suggests a time-related implication of digits and knees during collagen-induced arthritis development. These results
provide evidence for local alterations whereby mast cells contribute to the initiation of inflammatory arthritis and
may be targeted in intervention strategies.
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Rheumatoid arthritis is a chronic inflammatory disease involving
complex immunologic mechanisms including inflammation,
immunologic tolerance and autoimmunity, all contributing
to the destruction of cartilage and bone.1,2 Active rheumatoid
arthritis is characterized by a strong inflammatory reaction and
hyperplasia of synovial tissue. Histologically there is presence of
T lymphocytes, B lymphocytes, macrophages and mast cells in
the synovial membrane and fluid compartment.3–5
Traditionally, mast cells and immunoglobulin E (IgE) have
long been associated with the pathogenesis of immediate
hypersensitivity reaction, the pathophysiologic hallmark of
allergic rhinitis, allergic asthma, and anaphylaxis.6 IgE-dependent
activation of mast cells leads to the secretion of preformed
mediators (such as vasoactive amines and neutral proteases),
proinflammatory lipid mediators, that are synthesized anew,
and growth factors, cytokines and chemokines.7 However,
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mast cells can be activated to perform important effector
and immunomodulatory functions by mechanisms that are
independent of IgE; thus, the type of stimulus can determine
the kinetics, amounts and/or spectrum of mediators that are
released from this cell type.7–10 As an example, mast cells are
involved in autoimmune disorders and many of the pro-
inflammatory and tissue destructive mediators produced by
these cells have been directly implicated in the pathogenesis
of rheumatoid arthritis and other rheumatic diseases.5,11
Although mast cells have been implicated in arthritis, the
exact mechanism(s) by which they cause damage has not
been defined. One possibility would be that the proteases that
are released upon degranulation, eg, chymases, contribute to
disease. Recent findings showed a pathogenic role of mouse
mast cell protease 4 (mMCP-4) in autoimmune arthritis.12 It
therefore seems likely that activated mast cells are a driving
force in propagating microenviromental inflammatory cir-
cuits, by recruiting other types of cells, perhaps the neu-
trophils,13 and inducing proteolytic and cytokine activities in
the local environment.14
Congruently, mice lacking mast cell tryptase/heparin
complexes have attenuated arthritic responses; mouse mast
cell protease (mMCP-6) appears to be the dominant tryptase
responsible for favoring neutrophil infiltration in the K/BxN
mouse serum-transfer arthritis model.15 The biologic con-
sequences of the activation and degranulation of mast cells in
the rheumatoid synovial tissue are complex and despite their
ability to mediate inflammation was neglected for years, the
mast cell and its products are now recognized as novel targets
for therapy of rheumatoid arthritis.14
The anti-allergic nedocromil is a ‘cromoglycate-like’ drug
(cromolyn) that impairs the release of inflammatory mediators
from activated mast cells.16 Whereas nedocromil possesses
anti-allergic properties,3,17 its potential impact on classical
inflammatory and arthritic responses is less studied. Thus, we
have used here a model of rheumatoid arthritis, the collagen-
induced arthritis (CIA) in the mouse, to monitor mast cell
status in two distinct joints; we have then tested the effect of
a mast cell stabilizer in comparison to a well-accepted anti-
arthritic therapy, the glucocorticoid prednisolone.
MATERIALS AND METHODS
Animals
DBA/1J male mice weighing 18–22 g (Harlan, UK) each were
used for all experiments. Animals were maintained on a
standard chow pellet diet with tap water ad libitum and
housed at a density of five animals per cage in a room with
controlled lighting (lights on from 8:00 a.m. to 8:00 p.m.) in
which the temperature was maintained at 21–231C. Animal
work was performed according to UK Home Office regula-
tions (Guidance on the Operation of Animals, Scientific
Procedures Act 1986) and this study was approved by the
Committee of Ethics in Research of the Sa˜o Paulo School of
Medicine, UNIFESP (CEP-process 0951/05).
Collagen Induced Arthritis (CIA)
Bovine type II collagen (CII) was dissolved at 41C in 0.1M
acetic acid to a concentration of 2mg/ml. Mice were im-
munized intradermally, at the base of the tail, with 100 mg
bovine CII emulsified in an equal volume of Freund’s
incomplete adjuvant (Sigma, UK) and Mycobacterium
tuberculosis H37Ra (Gibco; 2mg/ml). Booster injection of
CII dissolved in Freund’s incomplete adjuvant was given
21 days after the first immunization. Nonimmunized mice
received similar injections but without the antigen CII.
DBA/1J mice were divided into 4 experimental groups, with 5
animals each. Mice were killed 21, 32 or 42 days after the first
immunization.
Drug Treatments
Sodium nedocromil (generous gift of Sanofi-Aventis,
London, UK; 2mg/kg) and prednisolone (21-Hemisuccinate
salt, Sigma-Aldrich, Poole, UK; 4mmol/kg) were given orally
or subcutaneously, respectively, over a 10 day period starting
at day 22. Compounds were diluted with sterile saline
immediately before use.
Assessment of Clinical Score and Paw Volume
A clinical score was allocated to each mouse every other day
from day 7 to day 42. The clinical severity of arthritis was
quantified according to the swelling of four paws.
For scoring, each paw was evaluated for paw and digit
swelling. For each hind paws a maximum score of 6 was given
(12 max for both), giving a value of 1 for each toe5 and a
value of 1 for the total assessment of the paw. For the fore-
paws, a maximum of 5 could be reached (max 10 for both),
counting 1 for each toe (hence max possible of 4) and 1 for
the paw (in the forepaw the pollex was not considered for
scoring). With respect to the affected toes, there was no
distinction if one or more than one joint in the same toe were
affected, so the max scored is 1. Redness was not considered
itself for scoring but only as contributor to the score of a
given toe when accompanied by mild swelling. When each
single paw was graded a maximal score of 22 could be given
to each mouse.
Paw volumes were assessed daily from day 7 to day 42 after
immunization, using a hydropletysmometer (Ugo Basile,
Milan, Italy). Paw volume was calculated in ml by subtracting
the initial paw volume (basal) to the values measured at each
time point (oedema). The knees were not evaluated macro-
scopically but only by histology.
Fixation, Processing, and Embedding for Light
Microscopy
The knees and digits joints were dissected and fixed in 4%
paraformaldehyde, 0.5% glutaraldehyde and 0.1mol/l so-
dium cacodylate buffer (pH 7.4) for 24 h at 41C. They were
then washed in sodium cacodylate, dehydrated through
graded percentages of methanol and embedded in LRWhite
(London Resin Co., Reading, Berkshire, UK). Sections (1 mm
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thick) were cut on an ultramicrotome (Leica RM2265, Leica,
Germany), stained with 1% toluidine blue in 1% borax so-
lution (TAAB Laboratories, Aldermaston, Berkshire, UK) and
by Picrosirius and hematoxylin-eosin (H&E-stain) methods.
Sections of digits and knees joints were analysed on an
Axioskop 2-Mot Plus Zeiss microscope (Carl Zeiss, Jena,
Germany) for quantification of mast cells and neutrophils.
The histological analysis was performed using a high power
objective (x63) in the microscope ZEISS – AXIOSKOP 2, by
counting cells in three areas with a minimum of approxi-
mately 100 mm2, using three distinct serial sections (50 mm
interval between sections) per animal, for five different animals.
The presence of mast cells and neutrophils was determined
in different areas of the synovial tissue and joint space.
Degranulated mast cells were identified by the reduced
presence of cytoplasmatic granules. Values are shown as
mean±s.e.m, of cells number permm2).
Data Handing and Statistical Analysis
Quantification of neutrophils and mast cells number in the
digits and knees synovial tissue was performed with the
image analysis system (AxioVision Software, Zeiss) (analyz-
ing at least five distinct sections per mouse). The histological
analysis was performed using a high power objective (x63) in
the Axioskop 2-Mot Plus Zeiss microscope (Carl Zeiss, Jena,
Germany). This also allowed morphological analysis of mast
cell degranulation as determined by the presence of extra-
vasated cytoplasmic granules in the tissue. Data are reported
as mean±s.e.m. of n¼ 5 mice per group. Experimental
groups were analysed using one way ANOVA followed by
Dunnett’s or post hoc test for linear trend between means, as
appropriate (42 groups, parametric data), or Student’s t-test
for two selected groups. P-Values lower than 0.05 were con-
sidered significant.
RESULTS
Time-Course of CIA in DBA/1J Mice
The development of inflammation was assessed by scoring
the clinical disease activity and measuring changes in
paw volumes. Arthritis developed in DBA/1J mice after
intradermal injection of CII from Bday 20, with a rapid
clinical progression (Figure 1a) that we monitored up to day
42. With respect to the paw, during the initial phase a
moderate increase in the paw volume was noted (Figure 1b):
a significantly elevated level of inflammation was measured
on day 32, with a further exacerbation (Po0.001), through
some variations, up to day 42 (Figure 1b).
Histopathological Analysis of the Digits and Knees
Joints on CIA
Histopathologic analysis of picrosirius and H&E-stained
tissue sections demonstrated accumulation of transmigrated
neutrophils in the digits, which steadily increased from day
21, reaching a peak at day 32 post-CII (Figure 2a–i). In the
knee synovial tissue samples, neutrophil number was also
modulated by the immune response to CII, but the peak was
now reached by day 21, followed by a substantial (450%)
reduction progressively to day 32 and day 42 (Figure 2j–r).
Moreover, there were statistical differences between digit and
knee neutrophils number (Po0.001, on 21, 32 and 42 days),
with a consistent lower presence of this cell type in the knee
synovial tissue.
In addition to the profile of neutrophil recruitment to the
synovial tissue, there were significant alterations in the in-
filtration of these cells within the joints. Analysis of serial
joint tissue sections showed significantly augmented neu-
trophil number in the knees joint space of DBA/1J mice
submitted to CIA, on day 21 (2,00±0.32 cells/mm2), day 32
(1,17±151.90 cells/mm2) and day 42 (641.40±0.50 cells/
mm2), in relation to non-arthritic animals, where this cell
type was rarely detected (5.1±1.90 cells/mm2).
Mast cells morphology was also analyzed both in digit and
knee synovial tissue samples, using toluidine blue staining.
Histology of the digits joints showed presence of intact mast
cells, with their characteristic metachromatic granules (Fig-
ure 3a–e): in some cases these cells were localized close to
blood vessels both in control mice and at day 21 of the CIA
response (Figure 3a and b). The number of degranulated
mast cells was constant over the period under observation
ranging between 31 and 35% for both day 21, 32 and 42
(Figure 3a–e). In contrast to these results in the digits, knees
joint sections displayed a lower total number of mast cells,
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Figure 1 Development and progression of collagen-induced arthritis (CIA) in DBA/1J mice. Clinical score (a) and paw volume (b) were analyzed from day 7
after collagen immunization until day 42. Clinical score demonstrated a progressive development of arthritis mainly after the booster, on day 21. It was
detected a significantly greater paw volume on day 32 with a peak on day 42. Values are the mean and s.e.m. taking a P-value less than 0.05 as significant
(n¼ 5 animals per group). **Po0.01 vs day 21 (one way ANOVA followed by test for linear trend between means and Dunnett’s post hoc test).
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but the large majority of them were degranulated: this effect
peaked at day 21 (480% degranulation) and decreased over
time up to o30% degranulation on day 42 (Figure 3f–j). In
addition, comparison of intact mast cells in the digits and
knees revealed a significant increase in the first compartment
(Po0.05 at both day 21, 32 and 42); moreover, the extent of
degranulated cells was also higher in the digits (Po0.01, day
32 and 42).
Effects of Prednisolone and Nedocromil
Treatment of mice with either prednisolone or nedocromil
inhibited development of arthritis after CII administration,
evident both for clinical score and paw volume measure-
ments. Of interest, these compounds exerted different pattern
of actions: the inhibition attained by prednisolone was high
and constant over time, evident both for the clinical score
and the paw volume (Table 1, data for day 27 and 32). In
contrast, nedocromil produced a significant degree of in-
hibition on the clinical score, higher than on paw volume; in
either case, the maximal effect was evident at day 27, with
much more modest values at day 32 (Table 1).
These macroscopic analyses were complemented by his-
tological determinations, performed on day 32. Treatment of
mice with prednisolone markedly reduced cell recruitment
both in digits (Table 2) and knees (Table 3). Images in Figure
4a–c provide representative snapshots of these effects. Pre-
dnisolone inhibited neutrophil infiltration in the digit by
480%, with a much more modest effect in the knee (B25%
inhibition; though statistically different, Po0.001). Mast cell
analysis revealed that prednisolone produced a marked
mastocytosis, with an approximate 10-fold increase in tissue
mast cell numbers both in digits and knee tissue samples
(Figure 4d–f; Tables 2 and 3) (Po0.001, both for intact
and degranulated mast cells). With respect to the extent of
degranulation, in the digits B33% of mast cells were
degranulated and a similar incidence was calculated after
treatment with prednisolone (Table 2); in the knees, however,
B66% of mast cell degranulation was calculated in untreated
arthritic mice, whereas B30% degranulation could be cal-
culated in the glucocorticoid group (Table 3).
Nedocromil exerted inhibitory properties on neutrophil
recruitment both in digit and knee joints, with a much higher
degree of efficacy in the latter tissue (Figure 4c–f) (Po0.001).
In fact, whereas neutrophil reduction in the digits wasB80%
(Table 2), it reached 495% in the knee joints (Table 3). It
was important to validate the effect of nedocromil on mast
cell integrity. Treatment with this compound did not provoke
mastocytosis and actually seemed to reduce total mast cell
numbers (40 vs 18 and 8 vs 2 mast cells per mm2 for digists
and knees, in arthritic and nedocromil-treated mice, re-
spectively). However, at this late time-point, the degree of
degranulation was modestly affected (Tables 2 and 3).
Consistent with these findings, statistical analysis clearly
showed difference in the number of intact and degranulated
mast cells between digits and knees (Po0.001).
DISCUSSION
Experimental arthritis is widely used as a preclinical model
predictive for drug efficacy in human settings. This is parti-
cularly true for the collagen-induced arthritis (CIA) model.18
Injection of bovine type II collagen would induce an immune
response with consequent B cell-dependent production of
specific antibodies which, by a mimicry phenomenon, will
deposit to joints of the mouse.19 This will cause an active
inflammatory response, which would lead, eventually, to
joint destruction. In fact, in experimental arthritis a large
number of neutrophils accumulate into the joints of mice,
which respond to collagen type II injection. Despite this
model relies on strong immune components, which is as-
sured by B cell expansion and T cell activation, the presence
of typical cell types of innate immunity like the neutrophil is
widely documented.1,2,20,21 To a certain extent, the active
phase of the collagen-induce arthritis model mimics the flare-
up phase of human rheumatoid arthritis. The mechanisms,
which would lead to such a marked infiltration of blood
borne neutrophils into the joints are not fully investigated.
A recently developed model of arthritis, that is the serum-
induced arthritis,22 has indicated a pivotal role for tissue
resident cells such as the mast cell and the macrophage in
bringing about the acute inflammatory arthritis which is
characterised by marked recruitment of neutrophils.23 When
mast cells are challenged by an external stimulus, often they
respond by degranulation. In this process, mast cells also
produce metabolites of arachidonic acid, including leuko-
trienes (LTC4 and LTD4) and prostaglandins, particularly
PGD2.
24 In addition, a number of powerful preformed
inflammatory ‘mediators’ are released, including cytokines
(IL-4, IL-5, IL-6, IL-13, TNF-a) and chemokines (eg CXCL1
and CCL2), histamine, serglycin proteoglycans, and several
mast cells-specific proteases (chymases, tryptases, and car-
boxypeptidase A; see references.25,26 Chymases and tryptases
are the major proteins stored and secreted by mast cells27 and
are potent chemotactic activities for neutrophils.28,29 Other
mediators, such as histamine, can have both positive and
negative immunomodulatory effects. Histamine can promote
neutrophil recruitment by increasing CD62P expression on
Figure 2 Neutrophils migration after CIA within the synovial tissue of digits and knees joints. Synovial tissue of the digits (a–i) and knees (j–r) displayed an
evident accumulation of transmigrated neutrophils (arrows) on days 21, 32 and 42 after collagen immunization. Data were analyzed using one way ANOVA
followed by Dunnett’s post hoc test. Results are expressed as the mean±s.e.m. taking a P-value less than 0.05 as significant (n¼ 5 animals per group).
**Po0.01 vs control group; Po0.001 vs digits. Picrosirius and H&E-stain; scale bars: (a, c, e, g, j, l, n, p) 20 mm; (b, d, f, h, k, m, o, q) 5 mm. v, vessel; st, synovial
tissue; b, bone.
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the endothelium, an effect achieved by activation of its type 1
receptor (H1).
30,31 Such an effect contribute to chemokine
induced leukocyte recruitment, as seen both for neu-
trophils32,33 and eosinophils.34 Moreover, histamine inhibits
neutrophil chemotaxis by acting on its type 2 receptor (H2)
hence an effect mimicked by the H2 agonist impromidine,
but not by the H1 agonist betahistine. H2 activation can also
mediate histamine-induced reduction of neutrophil activa-
tion, superoxide formation and degranulation.35,36 Finally,
histamine can have a positive effect on neutrophil recruit-
ment not only by activating the H1 receptors, but also via the
H4 receptor.
30,37 In more general terms, an appreciation of
the role that mast cells would play not only in allergic and
acute inflammation, but also in chronic settings, has recently
emerged and being appreciated.38,39
Mast cells functions in arthritis are underscored by the
findings that their activation and subsequent release of
mediators are essential to the CIA development.40,41 Studies
in mice lacking mast cells (W/Wv) have helped clarifying the
role of this cell type in arthritis as well as inflammation: these
mice failed to produce an inflammatory and erosive arthritis
after infusion of autoantibodies.38 Consequently, in the ab-
sence of mast cells, there was no clinical or histologic evi-
dence of arthritis into the joint. Although mast cells are
implicated in the initiating events that lead to inflammatory
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Figure 3 Mast cells in the digits and knees synovial tissue: histopathologic manifestations and quantification. Analysis of the digits (a–e) and knees (f–j)
joints showed intact (arrowheads) and degranulated (arrows) mast cells in toluidine blue-stained sections. Representative sections demonstrating
histopathology of a DBA/1J mice digits joints exhibiting a higher number of mast cells on day 21 in relation to the knees tissue; however, the level
of degranulated cells was higher in the knees. On days 32 and 42 degranulated mast cells number was similar in the digits but gradually decreased
in the knees. Data were analyzed using one way ANOVA followed by Dunnett’s post hoc test Results are expressed as the mean±s.e.m. taking a
P-value less than 0.05 as significant (n¼ 5 animals per group).**Po0.01 vs control group. Scale bars: 5 mm. v, vessel.
Table 1 Treatment of CIA mice with prednisolone and
nedocromil affects clinical scores and paw volumes
Time-post
CII (Day)
Clinical score Paw volume
Prednisolone Nedocromil Prednisolone Nedocromil
27 75.8±18.5 39.4±32.1 46.7±9.6 20.0±9.9
32 84.7±9.7* 23.8±21.9 66.7±9.1** 12.4±9.2
Data reported are percentages (%) of inhibition after treatment with Pre-
dnisolone (4mmol/Kg) and Nedocromil (2mg/Kg) from day 27 to day 32. Data
shown as Mean±s.e.m. of 5 mice per group. *Po0.05; **Po0.01 vs control
group day 32. Data were analyzed using one way ANOVA followed by
Dunnett’s post hoc test.
Table 2 Neutrophils and mast cells migration profile after
prednisolone and nedocromil therapy in the digits
Digits synovial tissue
Cell Type Untreated Prednisolone Nedocromil
Neutrophils 1,512±21.2 206±54.1*** 289±39.4***
Intact mast cells 27.5±1.9 203±20.0** 6.7±1.0***
Degranulated mast cells 12.5±2.3 137±10.4*** 10.6±0.4
Data report the number of the specified cell type per mm2 as quantified in
digit synovial tissue of arthritic mice on day 32. Mice were either left untreated,
or treated with Prednisolone (4 mmol/Kg) or Nedocromil (2mg/Kg) from day 21
to day 32. Values are mean±s.e.m. of 5 mice pre group. **Po0.01 and
***Po0.001 vs untreated arthritic group.
Table 3 Neutrophils and mast cells migration profile after
prednisolone and nedocromil therapy in the knees
Knee synovial tissue
Cell type Untreated Prednisolone Nedocromil
Neutrophils 1,266±15 1,174±41*** 54±4.8***
Intact mast cells 2.2±0.2 18.6±1.2*** 0.7±0.1**
Degranulated mast cells 5.4±0.1 6.7±1.0 1.3±0.1***
Data report the number of the specified cell type per mm2 as quantified in
the knee synovial tissue of arthritic mice on day 32. Mice were either left
untreated, or treated with Prednisolone (4 mmol/Kg) or Nedocromil (2mg/Kg)
from day 21 to day 32. Values are mean±s.e.m. of 5 mice pre group. **Po0.01
and ***Po0.001 vs untreated arthritic group.
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arthritis, the exact mechanism by which they cause damage
has not been defined.23
A novel outcome of the results presented here is a detailed
analysis of the changes in mast cell morphology during the
collagen-induced arthritis model over a wide time range.
Moreover, intense influx of neutrophils could also be de-
termined. Our detailed histological analyses of the digits and
knees tissue samples revealed a different level of infiltration,
suggesting that perhaps the disease starts in the latter before
propagating to the former tissue site. Or even if there isn’t
any function or temporal association, our results indicate
that neutrophil infiltration into the digits is much higher at
time points when overt disease occurred (eg day 32); this was
different from the profile of neutrophil tissue number in the
knees samples which peaked at day 21, ie, at the beginning of
the disease and then progressively decreased over time.
The importance of neutrophil trafficking has been de-
termined in several inflammatory conditions; an association
with CIA has recently been put forward, noting how neu-
tropenia is associated with a reduced CIA response. In
addition, depletion of neutrophils using specific antibodies,
once CIA is clinically established, would arrest disease pro-
gression, demonstrating a critical requirement for these cells
in perpetuating joint inflammation in these experimental
conditions.42
Having established, and in part confirmed, high presence of
neutrophils within the affected joints, with a detailed and dif-
ferential analysis between knees and digits, next we monitored
the number and phenotype of mast cells. Again, differences
between the two tissue sites emerged and this was also evident
when the degree of mast cell degranulation was determined: in
the knees, there is a high degree of mast cell degranulation at
day 21, that is, the disease onset, which then progressively
decreases over time. In contrast, in the digits, there is a much
higher number of mast cells at day 21 and the degree of de-
granulation remains, though with some fluctuations, constant
over time. Collectively, these results indicate that at disease
onset at peak of neutrophil influx and mast cell degranulation
occurs in the knees and these precede the persistent in-
flammatory response that then occurs in the digits.
The next step of our study was to modulate macroscopic
and histological outcomes testing the clinically active gluco-
Untreated Prednisolone Nedocromil
v
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Figure 4 Synovial tissue of the digits after prednisolone and sodium nedocromil therapy. Histological analysis showing the influx of neutrophils (a–c) and
mast cells (d–f) within the digits joints. Neutrophils (arrows) and intact (arrowheads) or degranulated (open arrows) mast cells were obtained from untreated
and mice administered with prednisolone or sodium nedocromil, on day 32 after CIA. Picrosirius and H&E-stain (a–c) and toluidine blue stains (d–f); scale
bars: 10 mm.
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corticoid prednisolone43 and the mast cell stabiliser nedo-
cromil.16,44 The glucocorticoid was used at a dose known to
produce anti-arthritic actions.45 Indeed, in our settings,
treatment of mice with prednisolone produces remarkable
inhibitory effects both on the clinical score and on changes in
volume. Nedocromil allowed us to test further the hypothesis
of mast cell involvement. However, treatment of mice with
this compound did not affect the clinical score in a significant
manner, whereas it produced significant reduction in paw
volume at its peak, eg. day 32. Analysis of the full time course
of the experimental disease indicates how the clinical score
begins (day 21), and in way precedes measurable increases in
paw volume (evident from day 25). But can we relate any of
these macroscopic pharmacological effects to changes in a
tissue infiltration by neutrophils and/or to a degree of control
of mast cell degranulation?
These analyses were conducted at day 32, since corre-
sponded to high values for clinical score, paw volume and
histological markers. Two well-known effects could be ob-
served in the group of mice treated with prednisolone; these
were a remarkable inhibition of neutrophil influx as well as
much higher numbers of tissue mast cells. The process of
neutrophil extravasation is extremely sensitive to the in-
hibitory effect of glucocorticoids including prednisolone.46,47
Glucocorticoids remain one of the most effective therapies
for treatment of mast cell-related disorders. Glucocorticoids
act in a time-dependent manner to potently suppress
degranulation and cytokine production in mast cells
in vitro.48–51 The fact that the prednisolone elicited the ex-
pected effects,52 though likely never investigated in such a
detailed manner, in two different joints of the same arthritic
mouse gave us confidence that the experimental system could
be used to study the effect of nedocromil.
To this end, it is very interesting how the mast cell stabi-
liser produced uneven effects on the knees and digits synovial
tissues. It can be noted that this compound did not provoke
mastocytosis but rather it seemed to reduce total mast cell
numbers at day 32; moreover it mildly affected the extent of
mast cell degranulation, however it is plausible that it pro-
duced an overall inhibitory effect upon mast cell related re-
sponses, in view of the large decrease of total mast cells. There
is scant knowledge that nedocromil can inhibit mast cell
proliferation and differentiation.53 In a model of intestinal
inflammatory process the colon of the rats treated with ne-
docromil sodium showed a significant decrease in the
number of mast cells, concomitantly with reduction in in-
flammation and fibrosis.53 Initial stabilization of mast cells
with nedocromil would reduce histamine release, reducing
agonism at the histamine H4 receptor that modulates selec-
tive recruitment of mast cells, hence affecting the amplifica-
tion of histamine-mediated immune responses.54 Of interest,
nedocromil properties on the mast cell were associated with a
highly significant reduction in the influx of neutrophils,
which was particularly evident in the digit tissue samples. In
addition, cromolyns display inhibitory activity in CIA,55 but
there are no studies revealing the effect of nedocromil during
the development of arthritis. However, cromoglycates are not
very potent suppressors of mast cells function, and their ef-
fect may not be entirely specific for this cell type.5
Considering that nedocromil produced an anti-in-
flammatory effect, which was more evident on paw volume,
whereas it did not significantly affect the clinical score, we
wish to propose that attenuation of the paw volume might
likely be consequent to an inhibition of the inflammatory
events within the digits. Along the same rational, we wish to
propose that changes in the clinical score are consequent, or
predictive, of inflammatory events within the knees. Mast cell
stabilisers, including cromolyn and more recently developed
synthetic compounds, are used in clinical settings to control
allergic responses56 which are highly reliant on mast cell
degranulation and activation. These compounds also possess
anti-inflammatory activities in acute settings,57 whereas their
potential ability to influence a chronic inflammatory process
has been rarely investigated.
Here we showed that bovine type II collagen induced an
inflammatory process characterized by mast cell degranula-
tion, suggesting a potential driving force in propagating in-
flammatory circuits leading to recruitment of blood-borne
neutrophils. However, the different degree of joint involve-
ment suggests a time-related implication for digits and knees
during CIA development. These results provide evidence for
local alterations where mast cells contribute to the initiation
of inflammatory arthritis and may be targeted in intervention
strategies.
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